Glaukos is focussed on the development and commercialisation of breakthrough products and procedures to transform the treatment of glaucoma. The company pioneered minimally invasive glaucoma surgery (MIGS) in order to revolutionise the traditional glaucoma treatment and management paradigm.
In 2016, Glaukos Australia launched the iStent inject. Delivering two preloaded trabecular micro-bypass stents with a single entry, iStent inject optimises the benefits of MIGS; it is designed to improve aqueous outflow through the natural physiological outflow pathway. iStent inject is intended to reduce intraocular pressure in adult patients diagnosed with mild to moderate POAG currently treated with ocular hypotensive medication. It can be implanted with or without cataract surgery.